![](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F228216%2F300x378%2F74272715b4%2Fio_biotech-300x378.jpg&w=3840&q=75)
![](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F228216%2F300x378%2F74272715b4%2Fio_biotech-300x378.jpg&w=3840&q=75)
News
March 9, 2018
IO Biotech enters clinical collaboration with MSD evaluating IO102 in combination with KEYTRUDA® (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win technology, announces it has entered into a collaborative agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), through a subsidiary, focused on the clinical evaluation of IO102 with KEYTRUDA® (pembrolizumab) in patients with non-small cell lung cancer (NSCLC).